 Shares of Mirati Therapeutics Inc. MRTX, -0.81 were up about 3 in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people with advanced or metastatic non-small cell lung cancer. The drug, Krazati, can be used in patients who have a KRAS mutation; Agilent Technologies Inc. A, 1.56 and Qiagen QGEN, 1.16 both have FDA-approved companion diagnostics that can test for the mutation. 